Yabao Pharmaceutical Group (600351.SH): GLX002 has obtained the notice of approval for clinical trial of the drug.

Yabao Pharmaceutical Group (600351.SH) announced that its wholly-owned subsidiary, Beijing Yabao Biopharmaceutical Co., Ltd. (referred to as "Yabao Biopharma"), has recently received the Approval Notification for Clinical Trial of GLX002 issued by the National Medical Products Administration (NMPA) (Notification No.: 2025LP03407). GLX002 is an improved new drug based on bosentan dispersible tablets, indicated for Pulmonary Arterial Hypertension (PAH) (WHO Group 1), mainly used to improve pulmonary vascular resistance (PVR) in pediatric patients aged 1 year with idiopathic or congenital PAH, and is expected to improve exercise capacity; it is also used to treat adult patients with WHO Functional Class II-IV Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity and reduce clinical deterioration.